Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025 | Press Releases

– 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment – – Full data set from RECOVER OLE highlighting clinical response, safety, efficacy,...

Reviva to Participate in the A.G.P. Healthcare Company Showcase

May 13, 2025 | Press Releases

CUPERTINO, Calif., May 13, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the...

Reviva to Participate in the Citizens Life Sciences Conference

Apr 29, 2025 | Press Releases

CUPERTINO, Calif., April 29, 2025 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

Apr 24, 2025 | Press Releases

CUPERTINO, Calif., April 24, 2025 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 31, 2025 | Press Releases

– Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 –...